ROS1 Gene Mutation: Clinical Trials

2 active not recruiting, 2 completed, 1 recruiting, 1 unknown. 5 Phase 2, 2 Not applicable.

By phase and status

Phase	Trials	Status
Phase 2	5	Completed 2, Active not recruiting 1, Recruiting 1, Withdrawn 1
Not applicable	2	Active not recruiting 1, Unknown 1

Follow ROS1 Gene Mutation: new trials by email Literature Review of ROS1 Gene Mutation trials Research Report on ROS1 Gene Mutation

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies Sensus Smartwatch Application, RX Cap, Fitbit Sense - Lung Cancer, EGFR Gene Mutation	Not applicable	Active not recruiting	University of Virginia	30	2022-08-25	2025-11-25
Endobronchial Ultrasound Needle Aspiration With and Without Suction No suction EBUS-TBNA, Passive suction through dedicated EBUS-TBNA syringe, Manual applied suction EBUS-TBNA through a pistol-grip syringe holder - Mediastinal Lymphadenopathy, Hilar Lymphadenopathy	Not applicable	Unknown	Università Politecnica delle Marche	306	2022-06-01	2022-05-26
Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation Osimertinib, Alectinib 150 MG, Crizotinib 250 MG - Non Small Cell Lung Cancer, EGFR Gene Mutation	Phase 2	Recruiting	Hunan Province Tumor Hospital	6000	2020-04-16	2024-10-22
Genetic Testing in Guiding Treatment for Patients With Brain Metastases Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib - CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain	Phase 2	Active not recruiting	Alliance for Clinical Trials in Oncology	50	2019-10-17	2026-10-30
A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab, Carboplatin + Pemetrexed + Atezolizumab - NSCLC Stage IIIB, NSCLC Stage IV	Phase 2	Completed	Centre Francois Baclesse	150	2019-09-26	2026-05-12
Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers Brigatinib, Laboratory Biomarker Analysis, Quality-of-Life Assessment - Advanced Malignant Neoplasm, ALK Fusion Protein Expression	Phase 2	Withdrawn	Sameek Roychowdhury		2019-03-20	2022-02-18
Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 Laboratory Biomarker Analysis, Pembrolizumab, Recombinant EphB4-HSA Fusion Protein - ALK Gene Mutation, BRAF Gene Mutation	Phase 2	Completed	University of Southern California	42	2017-03-10	2025-10-22

Narrower conditions

Carcinoma, Non-Small-Cell Lung (3)  ·  Brain Neoplasms (2)  ·  Lung Neoplasms (2)  ·  Neoplasm Metastasis (2)  ·  Lymphoma (1)  ·  Sarcoidosis (1)  ·  Squamous Cell Carcinoma of Head and Neck (1)  ·  Tuberculosis (1)

Broader conditions

Neoplasms (7)  ·  Neoplasms by Site (7)  ·  Lung Diseases (5)  ·  Respiratory Tract Diseases (5)  ·  Respiratory Tract Neoplasms (5)  ·  Thoracic Neoplasms (5)  ·  Bronchial Neoplasms (3)  ·  Carcinoma, Bronchogenic (3)  ·  Lung Neoplasms (3)  ·  Brain Diseases (2)  ·  Central Nervous System Diseases (2)  ·  Central Nervous System Neoplasms (2)  ·  Neoplasms by Histologic Type (2)  ·  Neoplastic Processes (2)  ·  Nervous System Diseases (2)

Interventions

Pemetrexed (2)  ·  brigatinib (2)  ·  entrectinib (2)  ·  1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine (1)  ·  Bevacizumab (1)  ·  Carboplatin (1)  ·  Cisplatin (1)  ·  Crizotinib (1)  ·  Drug Therapy (1)  ·  Erlotinib Hydrochloride (1)  ·  Gefitinib (1)  ·  Surveys and Questionnaires (1)  ·  abemaciclib (1)  ·  adagrasib (1)  ·  aflutinib (1)

Sponsors

Alliance for Clinical Trials in Oncology (1)  ·  Centre Francois Baclesse (1)  ·  Hunan Province Tumor Hospital (1)  ·  Sameek Roychowdhury (1)  ·  University of Southern California (1)  ·  University of Virginia (1)  ·  Università Politecnica delle Marche (1)

Countries

United States (4)  ·  China (1)  ·  France (1)  ·  Italy (1)

Top investigators

Jorge Nieva, MD (1)  ·  Priscilla Brastianos, MD (1)  ·  Ryan Gentzler, MD (1)  ·  Sameek Roychowdhury, MD (1)  ·  Yongchang Zhang, MD (1)

Results publications

PMID 26402427, PMID 30011388, PMID 30526587, PMID 32103709, PMID 32479604, PMID 36801605, PMID 38830303

NIH funding

P30CA014089 (1), P30CA016058 (1), U10CA180821 (1)